Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib vs Cabozantinib or Vandetanib in RET-Mutant Medullary Thyroid Cancer
NCT04211337Phase 3Active, not recruiting
- Sponsor
- Loxo Oncology
- Start
- Feb 2020
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 20
01
Overview
A Phase 3 trial of selpercatinib in Medullary Thyroid Cancer (MTC), sponsored by Loxo Oncology. Started Feb 2020; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT04211337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211337.